Recent Articles

October 21, 2016 8:29 am
Gur Roshwalb, M.D., Chief Executive Officer of Akari Therapeutics
An unlikely potential use in treating inflammatory and autoimmune diseases involves one of the natural world’s least-celebrated liquids: the saliva of a tick.
October 21, 2016 1:44 pm
Ryan Bushey
The biotech company announced new study results on Thursday for two experimental therapies.
October 21, 2016 4:20 pm
Ryan Bushey
Alkermes saw its shares surge on Thursday after releasing new trial data related to its experimental drug to treat major depressive disorder, ALKS 5461.
October 19, 2016 11:00 am
Thomas Jarrat, Associate Analyst, GBI Research
The sheer number of expirations and approvals means the structure of the market will shift significantly.
October 18, 2016 2:25 pm
Ryan Bushey
The funding will be allocated to a mix of academic institutions and private companies.
October 17, 2016 3:57 pm
Kenny Walter, Digital Reporter
New research is suggesting that a mild sedative could reduce the risk of delirium following an operation by up to 65 percent.
October 17, 2016 3:56 pm
Ryan Bushey
The drug maker initiated a series of wholesale price increases for therapies in three portfolios.
October 17, 2016 11:00 am
Elisa Lazzari, UCSD, The Conversation
The connection between aging and cancer has become a pillar in medicine.
October 14, 2016 8:29 am
Ryan Bushey
The site contained about 13 cannabis plants that stretched up to almost 3 feet long when they were placed across a 35-year-old man’s chest diagonally.
October 13, 2016 2:00 pm
Christos Michaelides, Ph.D., Neurology and Opthamology Analyst, GlobalData
Increasing global diagnosed prevalence of MDD and the potential introduction of six late-stage pipeline products will play a role in this growth.
Subscribe to Drug Discovery & Development